USE OF INTERACTING DRUGS DID NOT MODIFY TREATMENT EFFECTS OF APIXABAN VERSUS WARFARIN FOR ATRIAL FIBRILLATION: RESULTS FROM THE ARISTOTLE TRIAL

Jeffrey B. Washam,Stefan H. Hohnloser,Daniel Wojdyla,Dragos Vinereanu,John H. Alexander,Renato D. Lopes,Bernard Gersh,Michael Hanna,John Horowitz,Elaine Hylek,Steen Husted,Denis Xavier,Freek Verheugt,Lars Wallentin,Christopher B. Granger

USE OF INTERACTING DRUGS DID NOT MODIFY TREATMENT EFFECTS OF APIXABAN VERSUS WARFARIN FOR ATRIAL FIBRILLATION: RESULTS FROM THE ARISTOTLE TRIAL

2017

Jeffrey B. Washam
Stefan H. Hohnloser
Daniel Wojdyla
Dragos Vinereanu
John H. Alexander
Renato D. Lopes
Bernard Gersh
Michael Hanna
John Horowitz
Elaine Hylek
Steen Husted
Denis Xavier
Freek Verheugt
Lars Wallentin
Christopher B. Granger

Background: Warfarin is dependent on hepatic enzymes for metabolism while apixaban is a substrate for P-glycoprotein (P-gp) transport and hepatic CYP3A4 (3A4) metabolism. Medications that affect these pathways could modify the anticoagulant exposure and potentially their treatment effect. Methods:

Keywords:

Atrial fibrillation
Cardiology
Apixaban
Internal medicine
Warfarin
Medicine
treatment effect
CYP3A4
Diabetes mellitus
Anticoagulant

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations